Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.58 |
| ▸ | CCR5 | P51681 | 1/20 | 0.41 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.32 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.32 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.32 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13660535 | 0.82 | HRH3 (0.56) | HRH3CCR5CHRNB2CHRNA7CHRNA4 | |
| SCHEMBL4292349 | 0.82 | HRH3 (0.56) | HRH3CCR5CHRNB2CHRNA7CHRNA4 | |
| SCHEMBL13660570 | 0.81 | HRH3 (0.55) | HRH3ALDH1A1ATM | |
| SCHEMBL4292359 | 0.81 | HRH3 (0.55) | HRH3ALDH1A1ATM | |
| SCHEMBL13660571 | 0.77 | HRH3 (0.51) | HRH3ALDH1A1KDM4ECHRNA7 | |
| SCHEMBL4294203 | 0.77 | HRH3 (0.51) | HRH3ALDH1A1KDM4ECHRNA7 | |
| SCHEMBL5549987 | 0.77 | CHRNB2 (0.56) | ALDH1A1ACHEKDM4ECYP3A4RECQL | |
| SCHEMBL13660567 | 0.76 | HRH3 (0.53) | HRH3KDM2B | |
| SCHEMBL4292355 | 0.76 | HRH3 (0.53) | HRH3KDM2B | |
| SCHEMBL4297685 | 0.75 | HRH3 (0.58) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1756058-A1 | HISTAMINE-3 RECEPTOR ANTAGONISTS | Pfizer Products Incorporated (US) | 2007-02-28 | — | — | EP | claimed |
| WO-2005105744-A1 | HISTAMINE-3 RECEPTOR ANTAGONISTS | PFIZER PRODUCTS INC. | 2005-11-10 | — | — | WO | claimed |
| US-20050245543-A1 | Histamine-3 receptor antagonists | PFIZER INC | 2005-11-03 | — | — | US | claimed |
| US-20050245543-A1 | Histamine-3 receptor antagonists | PFIZER INC | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245543-A1 | Histamine-3 receptor antagonists | HRH3, HRH4, HRH2 | HRH3 1/4885CCR5 1119/4885KDM2B 2997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.